MYL3, Monoclonal Antibody

Anti-MYL3 Antibody (clone 3F8) IHC-plus; MYL3; CMH8; Cardiac myosin light chain 1; CMLC1; Myosin; light chain 3; alkali; Myosin light chain 3; Ventricular; skeletal; slow; VLC1; MLC1SB; MLC1V; Human MYL3

For Research Use Only. Not for use in diagnostic procedures.

Monoclonal

IgG1

3F8

Mouse

Human MYL3

Ascites

Ascites fluid, 0.03% sodium azide

Long term: -20 degree C; Short term: +4 degree C. Avoid repeat freeze-thaw cycles.

Small volumes of anti-MYL3 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

MYL3 encodes myosin light chain 3, an alkali light chain also referred to in the literature as both the ventricular isoform and the slow skeletal muscle isoform. Mutations in MYL3 have been identified as a cause of mid-left ventricular chamber type hypertrophic cardiomyopathy.

Immunohistochemistry (IHC - Paraffin), Western Blot (WB), ELISA (EIA)

ELISA (1:10000), IHC-P (1:200), WB (1:500 - 1:2000)

Anti-MYL3 antibody IHC of human skeletal muscle. Immunohistochemistry of formalin-fixed, paraffin-embedded tissue after heat-induced antigen retrieval. Antibody dilution 1:200.

Anti-MYL3 antibody IHC of human heart. Immunohistochemistry of formalin-fixed, paraffin-embedded tissue after heat-induced antigen retrieval. Antibody dilution 1:200.

21,932 Da

myosin, light chain 3, alkali; ventricular, skeletal, slow

myosin light chain 3; CMLC1; cardiac myosin light chain 1; ventricular/slow twitch myosin alkali light chain; myosin light chain 1, slow-twitch muscle B/ventricular isoform; myosin, light polypeptide 3, alkali; ventricular, skeletal, slow

Myosin light chain 3

CMLC1; MLC1SB  [Similar Products]

MYL3_HUMAN

MYL3 encodes myosin light chain 3, an alkali light chain also referred to in the literature as both the ventricular isoform and the slow skeletal muscle isoform. Mutations in MYL3 have been identified as a cause of mid-left ventricular chamber type hypertrophic cardiomyopathy. [provided by RefSeq, Jul 2008]

MYL3: Regulatory light chain of myosin. Does not bind calcium. Defects in MYL3 are the cause of familial hypertrophic cardiomyopathy type 8 (CMH8). Familial hypertrophic cardiomyopathy is a hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain. They can be readily provoked by exercise. The disorder has inter- and intrafamilial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death. CMH8 inheritance can be autosomal dominant or recessive.

Protein type: Motor; Motility/polarity/chemotaxis

Chromosomal Location of Human Ortholog: 3p21.3-p21.2

Cellular Component: I band; sarcomere; muscle myosin complex; cytosol; A band

Molecular Function: actin monomer binding; structural constituent of muscle; motor activity; myosin II heavy chain binding; calcium ion binding

Biological Process: skeletal muscle development; metabolic process; positive regulation of ATPase activity; regulation of striated muscle contraction; ventricular cardiac muscle morphogenesis; regulation of the force of heart contraction; cardiac muscle contraction; muscle filament sliding

Disease: Cardiomyopathy, Familial Hypertrophic, 8

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.